A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A administered orally as a monotherapy or in combination with an immune checkpoint inhibitor (ICI) in subjects with solid tumors.
Study details:
SR-8541A, an ENPP1 inhibitor, will be administered orally as a monotherapy to assess safety, tolerability, and pharmacokinetics (PK) in subjects with advanced/metastatic solid tumors. Subjects eligible for treatment include those whose disease is refractory to standard therapeutic options, or for which there are no standard therapeutic options available. All enrolled patients will orally administer SR-8541A daily.
Treatment may continue until the subject's disease worsens or another treatment discontinuation criterion is met. The combination part will only commence once the SRC has deemed it safe to proceed and a SR-8541A dose from the dose escalation part is selected as the RP2D. The ICI will be either nivolumab or pembrolizumab and dosing will be per SOC.
Both investigational products will start on C1D1. Treatment with ICI may be continued if SR-8541A is discontinued and treatment with SR-8541A may be continued after ICI is discontinued. Approximately 10 subjects will be enrolled.
Eligibility criteria
Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.
Inclusion criteria
- Life expectancy of at least 3 months
- Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1
- Histopathologically/cytologically confirmed advanced solid tumor, which is refractory to standard therapeutic options, or for which there are no standard therapeutic options.
- Measurable disease per RECIST v1.1
- Willing to provide archival or fresh tumor tissue during screening (required) and post-treatment (optional)
- Adequate hematologic, renal and hepatic function
Exclusion criteria
- Primary central nervous system (CNS) tumor
- Prior systemic anti-cancer treatment including other investigational agents, surgery, or radiation within 28 days or 5 half-lives, whichever is less
- Continuous systemic treatment with either corticosteroids (>10 milligram [mg] daily prednisone equivalents) or other immunosuppressive medications within 28 days
- Active autoimmune disease that has required systemic treatment in past 2 years
- History of documented congestive heart failure (New York Heart Association [NYHA] class II - IV); unstable angina; poorly controlled hypertension; clinically significant valvular heart disease; high-risk uncontrolled arrhythmias (including sustained ventricular tachycardia); myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack within the last 6 months, or Canadian Cardiovascular Society angina class > 2
- Troponin I > ULN
- Blood pressure (BP) - Systolic < 95 mmHg or > 160 mmHg or diastolic > 100 mmHg
- Resting heart rate (HR) > 100 beats per minute (BPM)
- Corrected QT interval by Fridericia (QTcF) ≥ 470 ms
- Left Ventricular Ejection Fraction (LVEF) < 50%
- Symptomatic uncontrolled CNS disease requiring treatment with steroids or anti-seizure medications within 2 months
- Leptomeningeal disease
- Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for at least 8 weeks
- Bleeding diathesis due to underlying medical condition or anticoagulation medication which is unable to be promptly reversed by medical treatment
- Prior additional malignancy that is progressing or has received treatment the previous 3 years
- Active infection requiring systemic treatment
- Positive for human immunodeficiency virus (HIV) (HIV antibodies) or active hepatitis B (e.g., HbsAg reactive) or active hepatitis C (e.g., HCV ribonucleic acid [RNA] qualitative) infection with detectable viral load
- Major surgery within 28 days prior to Day 1 and/or minor surgery (excluding biopsy) within 7 days
Eligibility
Age eligible for study : NA
Healthy volunteers accepted : No
Gender eligible for study: ALL
Things to know
Study dates
Study start:
Primary completion:
Study completion finish:
Study type
TREATMENT
Phase
- PHASE1
Study ID
NCT06063681
Intervention or treatment
DRUG: SR-8541A
DRUG: Immune checkpoint inhibitor (ICI)
Conditions
- Advanced / Metastatic Solid Tumor
You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.
Research sites nearby
Closest Location:
Scientia Clinical Research Ltd
Select from list below to view details:
Scientia Clinical Research Ltd
Randwick, New South Wales, Australia
Monash Health
Clayton, Victoria, Australia
Peninsula & South Eastern Haematology & Oncology Group
Frankston, Victoria, Australia
Loading map...
Who is running the clinical trial?
Stingray Therapeutics
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
| Participant Group/Arm | Intervention/Treatment |
|---|---|
EXPERIMENTAL: SR-8541A Monotherapy
| Drug: SR-8541A, Drug: Immune checkpoint inhibitor (ICI) |
What is the study measuring?
Primary Outcome
| Measure | Description | Time Frame |
|---|---|---|
| Frequency and severity of Adverse Events | Adverse events will be graded according to CTCAE v5.0. | From first dose of study drug through 30 days following the last dose of study treatment |
| Recommended Phase 2 Dose (RP2D) of SR-8541A | Based on evaluation of Dose Limiting Toxicities (DLT) | From first dose of study drug through 28 days following the first dose of study treatment |
Secondary Outcome
| Measure | Description | Time Frame |
|---|---|---|
| Maximum plasma concentration (Cmax) | Cmax measured in ng/mL | From first dose of study drug through 28 days following the first dose of study treatment |
| Area under the curve from zero up to time t (AUC0-t) | AUC0-t measured in ng.h/mL | From first dose of study drug through 28 days following the first dose of study treatment |
| Area under the concentration time curve from time 0 extrapolated to infinity (AUC0-inf) | AUC0-inf measured in ng.h/mL | From first dose of study drug through 28 days following the first dose of study treatment |
| Maximal time for peak concentration (Tmax) | Tmax measured in h | From first dose of study drug through 28 days following the first dose of study treatment |
| Terminal phase rate constant (λz) | λz measured in 1/h | From first dose of study drug through 28 days following the first dose of study treatment |
| Half-life (t1/2) | t1/2 measured in h | From first dose of study drug through 28 days following the first dose of study treatment |
| Overall Response Rate | Defined as the proportion of subjects in the efficacy population who achieve a radiographic investigator-assessed confirmed complete response (CR)/immune CR (iCR) or partial response (PR)/immune PR (iPR) per RECIST v1.1 or immune Response Evaluation Criteria in Solid Tumors (iRECIST) v1.0 | From first dose of study drug through 2 years following first dose |
| Progression Free Survival | Defined as the time from start of treatment to the first documentation of progressive disease (PD) or death from any cause, whichever occurs first | From first dose of study drug through 2 years following first dose |
| Duration of Response | Defined as the time from the date a response of PR or better was first recorded to the date on which PD was first noted or the date of death due to any cause | From first dose of study drug through 2 years following first dose |
| Disease Control Rate | Defined as the proportion of subjects who achieve an investigator-assessed confirmed CR/iCR, PR/iPR, or Stable Disease (SD)/immune SD (iSD) at 16 weeks per RECIST v1.1 or iRECIST v1.0 | From first dose of study drug through 2 years following first dose |
| Overall Survival | Defined as the time from the start of treatment until death due to any cause | From first dose of study drug through 2 years following first dose |
References
Clinical Trials Gov: A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid TumorsOther trials to consider
Loading suggested trials...
